[3] These include poor growth, apathy, having no desire for food, and developmental regression
ESM1 (download DOCX (DOCX 25.9 KB) Rights and permissions Springer Nature or its licensor (e.g
However, this is a top-line result announced by the company, and as of July 2026, it remains an unapproved investigational drug
1 2 "JUICEScience objectives"
Whether you plan to stay on a maintenance dose, taper off completely, or cycle on and off, the habits you build during treatment determine your long-term outcome
Important safety information: CagriSema is an investigational once-a-week injection combining cagrilintide and semaglutide